Study guide
2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
AACN Cardiac Medicine Certification CMC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview and the CMC Test Plan
1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them
2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease
2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease
3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup
4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions
4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation
5 Chapter 5: Vascular Conditions and Vascular Interventions
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
6 Chapter 6: Shock States and Mechanical Circulatory Support
6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
7 Chapter 7: Cardiac Procedures and Structural Heart Interventions
7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications
8 Chapter 8: Cardiovascular Pharmacology
8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure
9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary
9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients
10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients
11 Chapter 11: Monitoring and Diagnostics
11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography
12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions
12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease
2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
Key Takeaways Explain This Topic AI
High-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily) lowers LDL-C by 50% or more and is started or continued before discharge in every ACS patient regardless of the admission LDL-C.
In very-high-risk ASCVD an LDL-C of 70 mg/dL or higher on maximally tolerated statin triggers a non-statin add-on: ezetimibe adds 13-20%, PCSK9 monoclonals and inclisiran add about 50-60%, bempedoic acid 17-25%.
Most statin-associated muscle symptoms occur with a normal creatine kinase; myopathy is CK above 10 times the upper limit of normal and rhabdomyolysis above about 40 times normal with myoglobinuria.
Simvastatin is capped at 20 mg daily with amiodarone, amlodipine or ranolazine and 10 mg daily with verapamil or diltiazem, and gemfibrozil should not be combined with any statin.
Statin discontinuation after ACS is associated with increased mortality, so teach patients to call about muscle symptoms rather than self-discontinue, and place the cardiac rehabilitation referral before discharge.
Last updated: August 2026
Why Hyperlipidemia Sits on a Critical-Care Blueprint
The CMC test plan lists hyperlipidemia as sub-topic I.B.4 under Vascular Conditions, and chronic coronary disease underlies nearly every acute presentation on the unit. The exam is not asking you to run a lipid clinic. It is asking whether the cardiac nurse can identify the patient whose therapy is inadequate, recognize the adverse effects and drug interactions that surface in an intensive care environment, and deliver the discharge teaching that determines whether the plaque you just stented stays quiet.
Plaque Progression and the Concept of Stability
Atherosclerosis begins with endothelial injury and subendothelial retention of apolipoprotein B-containing lipoproteins : low-density lipoprotein (LDL), remnant particles, and lipoprotein(a). Oxidized LDL is engulfed by macrophages, which become foam cells and form the fatty streak . Smooth muscle cells migrate outward and lay down a collagen fibrous cap over an enlarging necrotic lipid core, producing the fibroatheroma. Vessels initially remodel outward (Glagov remodeling), so a plaque can be biologically advanced before angiography shows any narrowing.
What produces an acute event is not stenosis severity but cap integrity :
Thin-cap fibroatheroma (TCFA) is a cap thinner than roughly 65 micrometers over a large lipid core with dense macrophage infiltration. Rupture of a TCFA causes about two-thirds of acute coronary syndromes, and most culprit lesions were less than 70% stenotic beforehand. This is why a reassuring stress test months earlier does not exclude ACS today, and it is a favorite exam trap.
Plaque erosion is endothelial denudation over a proteoglycan-rich, less inflamed plaque. It accounts for roughly a quarter to a third of ACS and is relatively more common in younger patients, women, and smokers.
Calcified nodule is a minority mechanism seen in elderly, heavily calcified and renal-failure vessels.
Lipid lowering works by changing this biology. Aggressive LDL reduction shrinks the lipid core, thickens the fibrous cap and reduces macrophage content, and at LDL-C values below roughly 70 mg/dL serial intravascular ultrasound studies demonstrate net plaque regression. That mechanism, plaque stabilization rather than cholesterol arithmetic , is also the version you teach the patient.
Chronic Coronary Disease and Angina Severity
Chronic coronary disease (CCD) is the term used by the 2023 AHA/ACC chronic coronary disease guideline in place of "stable ischemic heart disease." It covers patients after acute coronary syndrome or revascularization, patients with stable angina, ischemic cardiomyopathy, vasospastic or microvascular angina, and patients with coronary disease found on imaging. Grade the symptom burden with the Canadian Cardiovascular Society (CCS) class, because that is what drives escalation and what an exam stem uses as shorthand.
- CCS class Description
- I Angina only with strenuous, rapid or prolonged exertion; ordinary activity is not limited
II Slight limitation: angina walking more than two blocks on the level or climbing more than one flight of stairs at a normal pace
III Marked limitation: angina walking one to two blocks on the level or climbing one flight of stairs at a normal pace
IV Inability to perform any physical activity without discomfort; anginal symptoms may occur at rest
The class alone is never the whole answer. A patient who moves from CCS II to CCS III or IV over a few weeks has a crescendo pattern, which is by definition unstable angina and belongs in an acute evaluation pathway rather than a routine outpatient titration.
The Lipid Panel and Current Targets
Measure How derived Where it matters
LDL-C Calculated (Friedewald) or measured directly Primary treatment metric; 70 mg/dL is the threshold for adding non-statin therapy in very-high-risk ASCVD, and many clinicians drive toward below 55 mg/dL after recurrent events
Non-HDL-C Total cholesterol minus HDL-C More reliable than LDL-C when triglycerides are elevated; goal is generally 30 mg/dL above the LDL-C goal, so below 100 mg/dL when the LDL-C goal is below 70
Triglycerides Measured 150-499 mg/dL is moderate hypertriglyceridemia; 500 mg/dL or higher is severe and carries pancreatitis risk
Lipoprotein(a) Measured once in a lifetime 50 mg/dL or about 125 nmol/L and above is a risk-enhancing factor; genetically determined and not meaningfully lowered by statins
Apolipoprotein B Measured Counts atherogenic particles; useful when LDL-C looks acceptable in diabetes or metabolic syndrome
Very-high-risk ASCVD , the category that triggers the most aggressive therapy, means a history of multiple major ASCVD events (acute coronary syndrome, myocardial infarction, ischemic stroke, symptomatic peripheral arterial disease) or one major event plus multiple high-risk conditions such as age 65 or older, diabetes, hypertension, chronic kidney disease, current smoking, heart failure, prior bypass or PCI, or a persistent LDL-C of 100 mg/dL or higher despite maximal therapy. Screening lipid panels no longer require fasting unless triglycerides exceed roughly 400 mg/dL.